News • Blog
Sexual health and LGBT population
Living with HIV
Post-exposure prophylaxis (PEP)
Several measures can help guard against HPV infection. However, they’re not all equally effective.
Health Canada is responsible for establishing the rules that companies must follow in advertising their vaccines. Below, we provide the indications for each of the two HPV vaccines available in Canada.
CERVARIX™ is a vaccine indicated in females from 10 to 25 years of age for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) by protecting against the following precancerous or dysplastic lesions caused by oncogenic Human Papillomavirus (HPV), types 16 and 18:
The effectiveness of Cervarix has not been studied in men. In women, this vaccine is effective only against cervical lesions.
GARDASIL® is a vaccine indicated in girls and women 9- through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, and 18 and the following diseases associated with the HPV types included in the vaccine:
GARDASIL® is indicated in girls and women 9- through 26 years of age for the prevention of:
GARDASIL® is indicated in boys and men 9 through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and the following diseases associated with the HPV types included in the vaccine:
Both HPV vaccines are usually administered in three doses over six months. You should not receive all three doses in less than a six-month period. However, if you miss a dose, you can receive it later, at your earliest convenience, without needing to restart the regimen.
The administration procedure is determined by your regional health board.